Skip to content
Benefits & EvidenceEvidence-Tiered

Angiotensin-(1-7) Benefits

What does Angiotensin-(1-7) actually do? We break down the evidence by tier — human data, animal studies, and in vitro research — with citations for every claim.

Quick Answer

Angiotensin-(1-7) offers vasodilation, anti-inflammatory, and anti-fibrotic benefits by activating the Mas receptor. It shows promise in treating heart failure, pulmonary hypertension, and kidney disease. Animal studies demonstrate cardioprotective and renal-protective effects. Clinical trials explore its potential to counteract the harmful effects of angiotensin II.

→ Angiotensin-(1-7) Dosage→ Angiotensin-(1-7) Side Effects→ Full Angiotensin-(1-7) Profile

Evidence Tiers

HumanClinical or observational human dataAnimalPreclinical in vivo studiesIn VitroCell / tissue culture studies
Table of Contents

Mechanism of Action

Angiotensin-(1-7) activates the Mas receptor, a G protein-coupled receptor. This activation leads to vasodilation through nitric oxide and prostacyclin release. It also inhibits MAPK/ERK pathways, reducing cell proliferation, and suppresses NF-κB and pro-inflammatory cytokine production, offering anti-inflammatory effects. Furthermore, it reduces TGF-β signaling, inhibiting fibrosis and enhancing bradykinin activity.

Human Evidence

Human2 findings

Improved hemodynamics in heart failure patients (investigational)

Limited clinical studies show Angiotensin-(1-7) can improve cardiac output and reduce pulmonary artery pressure in heart failure patients. These studies are primarily phase 1 and phase 2 trials.

PubMed 25827180 (2015) ↗

Reduced pulmonary artery pressure in pulmonary hypertension (investigational)

Early clinical trials suggest that subcutaneous Angiotensin-(1-7) (TXA127) may reduce pulmonary artery pressure and improve exercise capacity in patients with pulmonary hypertension.

PubMed 31501063 (2019) ↗

Animal Studies

Animal3 findings

Cardioprotection against ischemia/reperfusion injury

Animal models show Angiotensin-(1-7) reduces infarct size and improves post-ischemic recovery, indicating cardioprotective effects. This effect is mediated by the Mas receptor.

PubMed 18502904 (2008) ↗

Anti-fibrotic effects in cardiac, pulmonary, and renal tissues

Angiotensin-(1-7) reduces fibrosis in various animal models of organ damage, including cardiac fibrosis, pulmonary fibrosis, and renal fibrosis. This is achieved by reducing TGF-β signaling.

PubMed 24696328 (2014) ↗

Renal protection in diabetic nephropathy models

Animal studies indicate that Angiotensin-(1-7) preserves glomerular filtration and reduces proteinuria in models of diabetic kidney disease. This suggests a renal-protective effect.

PubMed 27616750 (2016) ↗

In Vitro Research

In Vitro2 findings
In vitro (cell culture) findings are the earliest stage of evidence. They indicate mechanism plausibility but cannot confirm human effects.

Vasodilation through nitric oxide release

In vitro studies demonstrate that Angiotensin-(1-7) induces vasodilation by stimulating nitric oxide (NO) release from endothelial cells. This is a key mechanism for its blood pressure-lowering effects.

PubMed 17344462 (2003) ↗

Inhibition of vascular smooth muscle cell proliferation

In vitro, Angiotensin-(1-7) inhibits the proliferation of vascular smooth muscle cells, which contributes to its anti-fibrotic and anti-atherosclerotic effects.

PubMed 18502904 (2008) ↗

What's Proven vs What's Still Unknown

✓ What the Evidence Supports

  • ✓Vasodilation via Mas receptor activation and nitric oxide release
  • ✓Reduction of cardiac, pulmonary, and renal fibrosis in animal models
  • ✓Anti-inflammatory effects by suppressing NF-κB and pro-inflammatory cytokines
  • ✓Cardioprotection in preclinical models of ischemia/reperfusion injury

? Still Unknown or Unconfirmed

  • ?Long-term efficacy and safety in human clinical trials
  • ?Optimal dosing regimens for specific human conditions
  • ?Effectiveness of oral formulations (currently under development)
  • ?Impact on overall mortality and cardiovascular outcomes

Frequently Asked Questions

What are the primary benefits of Angiotensin-(1-7)?
The main benefits include vasodilation, anti-inflammatory effects, and anti-fibrotic properties. It also shows promise in cardioprotection and renal protection, primarily demonstrated in animal models and early clinical trials.
How does Angiotensin-(1-7) benefit the cardiovascular system?
Angiotensin-(1-7) benefits the cardiovascular system by promoting vasodilation, reducing blood pressure, protecting against ischemia/reperfusion injury, and preventing cardiac fibrosis. It counteracts the harmful effects of angiotensin II.
Has Angiotensin-(1-7) been proven effective in humans?
While early clinical trials show promising results, particularly in improving hemodynamics in heart failure and reducing pulmonary artery pressure in pulmonary hypertension, more extensive and long-term human studies are needed to confirm its efficacy.
How does Angiotensin-(1-7) compare to ACE inhibitors?
ACE inhibitors block the conversion of angiotensin I to angiotensin II, indirectly increasing Angiotensin-(1-7) levels by reducing the substrate available for ACE2. Angiotensin-(1-7) directly activates the Mas receptor to produce beneficial effects, potentially offering a more targeted approach.
Is Angiotensin-(1-7) an antioxidant?
While Angiotensin-(1-7) does not directly function as an antioxidant, it can reduce oxidative stress indirectly through its anti-inflammatory and anti-fibrotic effects. It modulates pathways that contribute to oxidative damage.

References

  1. 1
    Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas(2003)PubMed ↗
  2. 2
    The ACE2/angiotensin-(1-7)/Mas axis: therapeutic target in cardiovascular disease(2015)PubMed ↗
  3. 3
    Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion(2008)PubMed ↗
  4. 4
    ACE2, angiotensin-(1-7), and Mas receptor axis in inflammation and fibrosis(2014)PubMed ↗

Last updated: 2026-02-19